MerlinTrader Learning Library

Educational Guides, Courses and Trading Frameworks

This library brings together MerlinTrader’s educational material on biotech catalysts, FDA regulation, clinical data, valuation, dilution, exchange compliance, market structure and trading psychology. Use the search field to find a topic, course chapter or practical guide. The material is educational only and is designed to help readers understand risk, evidence and market mechanics before evaluating an individual stock.

Browse Educational Resources 25
GlossaryBiotech & Trading Glossary: PDUFA, FDA & Small Caps GuideBiotech Trading Without the Fairy Tales SeriesBiotech Stocks Saga CourseRunUP Biotech Masterclass Chapter 1Biotech Catalyst Trading Guide Chapter 2How to Read Clinical Trial Results Chapter 3PDUFA Dates and FDA Reviews Chapter 4Biotech Valuation Framework Chapter 5Biotech Due Diligence Checklist StrategyRunUP Biotech Strategy Guide ItalianoStrategia Run Up Biotech EnergyRunUp Energy 2026 AnalysisAnalyst Price Targets in Biotech MarketsBetting on the FDA: How Kalshi’s Biotech Prediction Markets Work FDA 101CRL 101: Understanding FDA Complete Response Letters FinanceDilution, ATM Offerings, PIPE Deals and Reverse Splits Myths Vol. 1Encyclopedia of Social Trader Myths Myths Vol. 2Encyclopedia of Social Trader Myths — Volume 2 Myths Vol. 3Encyclopedia of Social Trader Myths — Volume 3 Market StructureIndex Reconstitution Explained Nasdaq 101Nasdaq Delisting & Compliance 101 FDA FinancePriority Review Vouchers Explained PsychologyThe Ten Commandments of the Trader TradingThe Trend Is Your Friend TradingWhen Good News Is No Longer Enough

No matching educational resource found.

Latest Educational Articles

Browse the newest educational guides and market-learning articles published by Merlintrader.

  • Critical minerals midstream explainer cover - why processing wins the race, UAMY worked example
    Why The Critical-Minerals Race Is Won In The Midstream, Not The Mine ($UAMY, $MP, $USAR, $TMC)
    A framework for reading the critical-minerals sector: why the real bottleneck is processing (the midstream), a four-question tool to triage any headline, with $UAMY as the worked example and $MP, $USAR and $TMC on the map.
  • Priority Review Voucher explained - RCKT DNLI FDA mechanism cover
    Priority Review Vouchers Explained: How an FDA Approval Becomes $180-205 Million in Cash, With $RCKT and $DNLI as Worked Examples · $XBI $IBB
    How Rare Pediatric Disease Priority Review Vouchers turn a single FDA approval into $180-205 million in non-dilutive cash – the mechanism explained, with $RCKT and $DNLI as worked examples.
  • Kalshi biotech prediction markets on FDA decisions and clinical trials, and what they mean for XBI and IBB
    Betting on the FDA: How Kalshi’s Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector
    Kalshi launched a pilot program on July 16, 2026, enabling trading on clinical trial outcomes and FDA decisions linked to biotech firms. This new prediction market offers a public price reflecting the probability of drug approval, but raises ethical concerns and potential manipulation risks due to limited participant knowledge and liquidity challenges.
  • Outlook Therapeutics $OTLK: A Story - the world's most-used eye drug is not approved for the eye, LYTENAVA wet AMD off-label economics
    Outlook Therapeutics ($OTLK): A Story — The World’s Most-Used Eye Drug Is Not Approved for the Eye
    Off-label economics explained with Outlook Therapeutics ($OTLK): why the most-used wet AMD treatment costs $50 and is not approved, while approved alternatives cost twenty times more. FDA PDUFA July 29, 2026.
  • ImmunityBio $IBRX: A Story cover - why FDA approval is only the starting line, Anktiva bladder cancer explainer
    ImmunityBio ($IBRX): A Story — Why FDA Approval Is Only the Starting Line
    An accessible three-act explainer using ImmunityBio ($IBRX) and its bladder-cancer drug Anktiva to show why FDA approval is only the starting line: the human stakes, the commercial launch curve, and who controls the company.
  • Reusable rockets launch economics explainer - $RKLB, $SPCX, China Long March 10B booster catch
    Reusable Rockets Explained: The Launch Economics, $RKLB as the Worked Example, and What China’s First Booster Catch Changes
    A plain-English guide to the economics of reusable rockets: why refurbishing beats rebuilding, how cost-per-kg collapsed, where SpaceX ($SPCX), Blue Origin, China’s Long March 10B and Rocket Lab ($RKLB) sit on the reuse ladder, a reusable triage for launch news, and what China’s first booster catch does and doesn’t change. Educational, not investment advice.
  • AI optical interconnect stack explained with POET Technologies as the optical-engine example
    Why AI Needs Optics: The Optical Interconnect Stack Explained, With POET as the Worked Example
    An educational guide to the AI optical interconnect stack – switch silicon, lasers, modulators, optical engines and modules – using POET Technologies (POET) as the highlighted optical-engine example.
  • Biotech & Trading Glossary by Merlintrader: PDUFA, FDA, cash runway and small caps
    Biotech & Trading Glossary: PDUFA, FDA & Small Caps
    70+ biotech, small-cap, FDA and trading terms explained clearly: PDUFA date, CRL, cash runway, short squeeze, surrogate endpoint and more.
  • Analyst
    Analyst Price Targets in Biotech: Why the Most Quoted Number Is Often the Least Useful One
    A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number.
  • trenfriend
    The Trend Is Your Friend
    There are trading phrases that survive because they are useful, and there are trading phrases that survive because they are easy to repeat. “The trend is your friend” belongs to both categories. It is useful, but only when treated as a probabilistic framework rather than a religious commandment. Used well, it keeps a trader aligned with momentum, liquidity, and market psychology. Used badly, it turns into a license to chase, overstay, and confuse a mature move with a fresh opportunity.
  • educ2
    When Good News Is No Longer Enough
    There are moments when a positive headline no longer lights a fire under a stock. It opens green, holds for a moment, then fades. That is not always an anomaly. Quite often, it is the market quietly telling you that the story alone is no longer enough.
  • trading myths3
    Encyclopedia of Social Trader Myths – Vol. 3The Self-Inflicted Edition
    The first myths of social trading usually come from outside: the trending ticker, the guru thread, the magical catalyst calendar, the cult of “smart money,” the promise that one more breakout will fix your year. But the deeper myths are the private ones. They appear after the chart turns ugly, after the timing fails, after the confidence starts cracking. That is when the internal narrator goes to work.This third volume is about those myths. Not the noisy lies from the feed, but the polished lies traders tell themselves when they need to protect pride, postpone discomfort, and keep a bad trade emotionally alive for just a little longer. These myths sound reasonable in real time. That is exactly why they are dangerous.
  • 10 commandaments
    The Ten Commandments of the Trader
    Why these commandments matter Many people think trading is mainly about finding the right stock, the right indicator, or the right catalyst. In reality, the hardest part is not the entry itself. The hardest part is making repeated decisions under uncertainty without letting emotion, urgency, ego, or frustration take control.That is why these commandments matter. They are not magic rules and they do not guarantee profits. What they do is far more useful: they help traders avoid some of the most common and expensive mistakes, especially in volatile environments where speed and pressure can easily lead to poor judgment.This page is designed as educational content for readers who want a stronger foundation. Before strategy comes discipline. Before conviction comes risk management. Before confidence comes process.
  • AI retail and Merlintrader
    When people talk about artificial intelligence in trading and investing, I almost always see two opposite – and both wrong – reactions.On one side you have those who demonise it by default: “it’s dangerous”, “it fills your head with nonsense”, “it’s useless, markets are moved by others anyway”. On the other side you have those who treat it like a modern oracle: “tell me what to buy”, “give me the next 10-baggers”, “build me the perfect watchlist”.I work with AI every single day to build Merlintrader’s content, and I can tell you something very simple: the truth is neither here nor there. AI is not an enemy to fight, and it’s not a guru to worship. It is a tool. Extremely powerful if you use it well. Dangerous if you use it badly. Useless if you ignore it.
  • Encyclopedia of Social Trader Myths – Vol. 2
    The slightly less polite, more cynical and more honest companion to the original Encyclopedia of Social Trader Myths. Same dark humour, more uncomfortable truths about how traders really behave on Stocktwits, Reddit, X and Discord.